Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Brett Logan Ecker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2536-9261; OpenAlex author ID A5055899792. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers, 1 trial

Papers 8

  1. Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes… Co-author DOI 10.1002/jso.70387↗
  2. Global cooperation and localized pancreatic cancer. Co-author DOI 10.1093/jnci/djag086↗
  3. SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Last author DOI 10.1097/sla.0000000000006966↗
  4. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.08.002↗
  5. Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration. First author DOI 10.1117/1.jmi.10.3.036002↗
  6. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  7. Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Char… Last author DOI 10.3390/biomedicines11113058↗
  8. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000212↗

Trials 1

  1. SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Principal investigator NCT07748611↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Howard S. Höchster · 1 shared paper, 2026 · strength 0.63
  2. Eileen Mary O'Reilly · 4 shared papers, 2022–2024 · strength 0.62
  3. William R. Jarnagin · 4 shared papers, 2022–2024 · strength 0.62
  4. Alice Chia-Chi Wei · 3 shared papers, 2022–2023 · strength 0.47
  5. Colin M. Court · 3 shared papers, 2022–2023 · strength 0.46
  6. Michael Ian D'Angelica · 2 shared papers, 2022–2023 · strength 0.30
  7. Quisette P. Janssen · 2 shared papers, 2022–2023 · strength 0.30
  8. Jeffrey A. Drebin · 2 shared papers, 2022–2023 · strength 0.30
  9. George Molina · 1 shared paper, 2026 · strength 0.25
  10. Judy Caroline Boughey · 1 shared paper, 2026 · strength 0.25
  11. Dhruv J. Patel · 1 shared paper, 2026 · strength 0.25
  12. David J. Bentrem · 1 shared paper, 2026 · strength 0.25
  13. Shishir Kumar Maithel · 1 shared paper, 2026 · strength 0.25
  14. Akhil Chawla · 1 shared paper, 2026 · strength 0.25
  15. John P. Hayes · 1 shared paper, 2026 · strength 0.25
  16. Julia Button · 1 shared paper, 2025 · strength 0.19
  17. Erin M. Dickey · 1 shared paper, 2025 · strength 0.19
  18. David G. Brauer · 1 shared paper, 2025 · strength 0.19
  19. Caitlin A. Hester · 1 shared paper, 2025 · strength 0.19
  20. Michael E. Lidsky · 1 shared paper, 2025 · strength 0.19
  21. Brian E. Diskin · 1 shared paper, 2025 · strength 0.19
  22. Elishama N. Kanu · 1 shared paper, 2025 · strength 0.19
  23. Ethan S. Agritelley · 1 shared paper, 2025 · strength 0.19
  24. Emil Lou · 1 shared paper, 2025 · strength 0.19
  25. Nipun B. Merchant · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.